First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study
一线替雷利珠单抗和奥西哌利单抗联合吉西他滨和顺铂治疗晚期胆道癌（ZSAB-TOP）：一项多中心、单臂、II期研究
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02356-y
Shi, Guoming; Huang, Xiaoyong; Ma, Liang; Li, Hui; Zhong, Jianhong; Wang, Junye; Gao, Qiang; Guo, Xiaojun; Qiu, Shuangjian; Sun, Huichuan; Shi, Yinghong; Huang, Xiaowu; Wang, Xiaoying; Yi, Yong; Zhu, Xiaodong; Huang, Cheng; Ding, Zhenbin; Chen, Yi; He, Yifeng; Shen, Yinghao; Sun, Qiman; Zhou, Jian; Fan, Jia
